Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Glatiramer acetate does not protect from acute ischemic stroke in mice.
Regional Susceptibility to TNF-α Induction of Murine Brain Inflammation via Classical IKK/NF-κB Signalling.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Molecular properties of epithelial, amiloride-blockable Na+ channels.
Genzyme's Lemtrada resubmission accepted for review by FDA
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Safety issue puts daclizumab in doubt for MS
Epigenetic changes in patients with multiple sclerosis.
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.

Pages